IRIS

Robert, C., Thomas, L., Garbe, C., Lebbe, C., Baurain, J.f., Testori, A., et al. (2011). Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma. EUROPEAN JOURNAL OF CANCER, 47(Supplement 1), S657-S658 [10.1016/S0959-8049(11)72527-8].

Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma

Maio M;
2011-01-01
2011
Robert, C., Thomas, L., Garbe, C., Lebbe, C., Baurain, J.f., Testori, A., et al. (2011). Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma. EUROPEAN JOURNAL OF CANCER, 47(Supplement 1), S657-S658 [10.1016/S0959-8049(11)72527-8].
1.5 Abstract in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1081028